Health
Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test – News-Medical.net
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expan…
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.
Avacta, in partnership with Cytiva, is developing a rapid test strip for use with patient saliva that aims to provide a result in a few minutes, indicating whether the patient is currently infected with the S…
-
Noosa News19 hours agoJazz festival wraps up | Noosa Today
-
Noosa News14 hours agoDog owners warned: $834 fine for pets not under control
-
Business18 hours ago5 things to watch on the ASX 200 on Thursday 4 September 2025
-
Noosa News16 hours agoPharmacist’s stolen image used in ‘dangerous’ deepfake adverts for weight loss drug